Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
about
Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia BGuidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveMethods to minimize the risks of Creutzfeldt-Jakob disease transmission by surgical procedures: where to set the standard?Paracrine diffusion of PrP(C) and propagation of prion infectivity by plasma membrane-derived microvesiclesTreatment of hemophilia B: focus on recombinant factor IX.BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia BvCJD and the gut: implications for endoscopyThe Krever Commission--10 years later.Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study.The variant Creutzfeldt-Jakob Disease: Risk, uncertainty or safety in the use of blood and blood derivatives?Emerging zoonoses and vector-borne infections affecting humans in Europe.Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells.Current options and new developments in the treatment of haemophilia.Haemophilia B: current pharmacotherapy and future directions.Prion diseases in humans: oral and dental implications.Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.Recombinant proteins in therapeutics: haemophilia treatment as an example.Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders.In vitro functional test of two subclasses of an anti-RhD antibody produced by transient expression in COS cells.The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products.BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).Reducing the risk of transfusion-transmissible viral infection through blood donor selection: the Australian experience 2000 through 2006.
P2860
Q28078281-C16DC0EA-3B34-4B67-A4EC-570356BE97FEQ28388806-C867304D-43F3-4FD2-A3AC-73648EF0221AQ30230440-7FD266D6-57C0-477D-81FE-4D2D1C2666D0Q33425214-84FAF31E-ECD8-477A-8406-2EE8956C9745Q34329068-BF391750-D848-4EDF-A74B-A3642272AFDBQ34348566-E48366AF-1A9B-4A5D-B035-B143047E33B7Q35761229-47B78E2C-1F98-46EB-8286-FECD381BCBD6Q36131212-CEA62B0B-C178-47F4-A0AE-AB445A6F08EDQ36588347-E294A1B1-5138-45C5-AC54-E75B37B54C56Q36743340-0CEEBC4D-0C46-4D46-8754-EB0C62A79505Q36796075-0200A8AB-BE74-487A-90C6-11B86BB999CAQ37234113-C06E5493-D0D0-43EB-862B-604459F342B0Q37841547-9B65D01B-5370-4910-BAEC-A93CE2FEA45FQ38040458-8B0C5973-2954-41C0-A2A7-E56C3493229CQ38135834-37D0206C-C28A-4A80-932C-3102C3219E02Q38151843-C2B342CD-44B9-4B0B-8B2D-F716C5697B44Q38444981-27527ACD-734C-4F03-854C-F37F1C45E0C9Q38912064-4C0C72CD-1ABB-4CFA-8A10-14DE93F8DCDDQ39871501-973B2CED-5214-482D-8E47-11A30EF81E4FQ40322065-3E1A5B8D-F89D-4875-BE92-EBE5963D81F7Q45757148-CF16CA8B-743B-4837-9D80-5F7E379CCBC4Q45865134-D266A34D-3039-45D7-A246-B6E07CFB7DBEQ45868068-61345539-CB0B-4AFE-9AA2-6668C86EEB93Q50675471-A70EBAED-A3A9-4793-BB03-F8313567D783
P2860
Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
@ast
Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
@en
type
label
Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
@ast
Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
@en
prefLabel
Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
@ast
Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
@en
P2860
P1476
Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
@en
P2093
Christopher A Ludlam
Marc L Turner
P2860
P356
10.1111/J.1365-2141.2005.05796.X
P407
P577
2006-01-01T00:00:00Z